文献速递慢性肾脏病肾血管病与高血压

铁剂对CKD患者心血管、肾脏及安全性结局影响的系统评价

Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD.
PubMed 文献 · Kidney Int Rep · 2025-01-29

该系统评价纳入45项随机试验,评估静脉或口服铁剂对CKD患者临床结局的影响。与常规治疗或安慰剂相比,铁剂降低心衰住院或心血管死亡复合终点风险(RR 0.84,95%CI 0.75-0.94),且严重不良事件发生率更低(RR 0.90,95%CI 0.82-0.98)。

要点

  • 铁剂可降低CKD患者心衰住院或心血管死亡复合终点风险。
  • 铁剂对透析与非透析CKD患者的效应一致。
  • 铁剂组严重不良事件发生率低于对照组。

核心结论

  • 铁剂治疗可能降低CKD患者心衰住院和心血管死亡风险,且严重不良事件发生率更低。

研究设计与样本

  • 系统评价与荟萃分析纳入45项随机试验,比较静脉或口服铁剂与常规治疗或安慰剂在CKD患者中的效果。

主要发现

  • 铁剂降低主要复合终点风险(1659例事件;RR 0.84,95%CI 0.75-0.94;中等确定性)。
  • 心衰住院风险降低(RR 0.77;95%CI 0.61-0.96;中等确定性)。
  • 心血管死亡风险无显著降低(RR 0.81;95%CI 0.65-1.02;低确定性)。
  • 严重不良事件发生率降低(RR 0.90,95%CI 0.82-0.98;中等确定性)。
  • 透析与非透析CKD患者效应一致(P-heterogeneity=0.70)。

临床怎么用

  • 对于CKD患者,可考虑铁剂治疗以降低心衰住院和心血管事件风险,尤其合并心衰或铁缺乏时。

局限性

  • 需要更多随机试验评估铁剂对非透析CKD患者(伴或不伴贫血)临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Heart failure and chronic kidney disease (CKD) are closely associated, and iron deficiency is highly prevalent in both conditions. However, major cardiovascular and nephrology guidelines offer contrasting recommendations for iron use. We evaluated the effects of iron versus usual care or placebo on the clinical outcomes in patients with CKD. METHODS: We conducted a systematic review and meta-analysis of randomized trials on i.v. or oral iron in patients with CKD (PROSPERO CRD42023453468). We searched Medline, Embase, and the Cochrane Register from database inception until February 1, 2024 to identify eligible trials. We determined the overall results and stratified them by dialysis- and nondialysis-requiring CKD using random effects models, with certainty of evidence assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach. The primary composite endpoint was hospitalization for heart failure or cardiovascular death. RESULTS: We identified 45 trials that met the inclusion criteria. Compared with usual care or placebo, iron reduced the risk of the primary composite endpoint (1659 events; risk ratio [RR]: 0.84, 95% confidence interval [CI]: 0.75-0.94; moderate certainty), an effect consistent across dialysis and nondialysis requiring CKD (P-heterogeneity = 0.70). The effect on the primary endpoint appeared driven by both components of hospitalization for heart failure (RR: 0.77; 95% CI: 0.61-0.96; moderate certainty) and cardiovascular death (RR: 0.81; 95% CI: 0.65-1.02; low certainty). The incidence of serious adverse events was lower for iron compared with usual care or placebo (RR: 0.90, 95% CI: 0.82-0.98; moderate certainty; P-heterogeneity = 0.09). CONCLUSION: Iron therapy may reduce the risk of heart failure and cardiovascular death in patients with CKD. Randomized trials evaluating the effects of iron on clinical outcomes are needed, especially in nondialysis patients with CKD with or without anemia.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Chan B, Varghese A, Badve SV, et al. Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD. Kidney Int Rep. 2025. PMID: 40303218. doi:10.1016/j.ekir.2025.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。